---
title: "Cognitive effects of methylphenidate in patients with Parkinson's disease with mild cognitive impairment."
euct_id: 2026-525701-12-00
phase: Phase 4
status: Not authorised
sponsor: Universidad Rey Juan Carlos
canonical_url: "https://parkinsonspathways.com/trials/eu/2026-525701-12-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2026-525701-12-00"
ctis_last_updated: "2026-06-09T03:37:36.580061018"
source: EU Clinical Trials Information System (CTIS)
---
# Cognitive effects of methylphenidate in patients with Parkinson's disease with mild cognitive impairment.

**EU CT Number:** [2026-525701-12-00](https://euclinicaltrials.eu/ctis-public/view/2026-525701-12-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Not authorised
- **Sponsor:** Universidad Rey Juan Carlos
- **Start Date:** 2026-06-01
- **Completion Date:** 2028-12-01
- **Conditions:** Parkinson's disease
- **Interventions:** Methylphenidate Viatris 10 mg tabletten, saccharine tablets

## Member States

Trial is authorized in 1 member state: Spain.

## Sites (1)

- Hospital Universitario Fundacion Alcorcon, Alcorcon, Spain

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: adults 18-64, elderly 65+
Sex: male, female

Period: Methylphenidate
Three months of methylphenidate
Arms:
  - Methylphenidate: 3 months of methylphenidate

Period: Placebo
3 months of placebo
Arms:
  - Placebo: 3 months of placebo
```

## What This Actually Involves

**Placebo** _(Ask the coordinator)_: The study's group design isn't in the registry data we have. Ask the coordinator whether there is a placebo group and what your chance of being assigned to it would be.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

---

*Canonical: https://parkinsonspathways.com/trials/eu/2026-525701-12-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2026-525701-12-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2026-525701-12-00*